BullFrog AI Appoints Josh Blacher as New CFO Following Predecessor's Passing

BullFrog AI Announces New CFO Appointment

BullFrog AI Holdings, Inc. (NASDAQ: BFRG, BFRGW), a technology-enabled drug development company leveraging artificial intelligence (AI) and machine learning, has appointed Josh Blacher as its new Chief Financial Officer (CFO), effective immediately 1

1

2

2

. This appointment comes in the wake of the untimely passing of Dane Saglio, the company's former CFO, who recently lost his battle with cancer.

Leadership Transition and Company Background

Vin Singh, CEO of BullFrog AI, expressed both sorrow at the loss of Dane Saglio and optimism for the future with Josh Blacher's appointment. Singh stated, "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and a cherished friend" 1

1

. He also welcomed Josh Blacher, emphasizing the importance of his experience in advancing the company's mission.

BullFrog AI is at the forefront of using AI and machine learning to revolutionize drug development. The company collaborates with leading research institutions and utilizes causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data. This approach aims to streamline therapeutics development and reduce failure rates in clinical trials 1

1

.

Josh Blacher's Background and Expertise

Josh Blacher brings over two decades of experience in strategic finance and corporate development for life science and biotech companies to his new role at BullFrog AI. His expertise includes:

1. Financial stewardship
2. Capital raising
3. Operations and profitability management
4. Deal making
5. SEC reporting oversight
6. Investor relations management for both private and public companies

Prior to joining BullFrog AI, Blacher held CFO positions at several companies, including Predictive Oncology, Rampart Bioscience, and Excision BioTherapeutics. He has also held senior roles at Teva Pharmaceuticals. Blacher's educational background includes a BA in Economics from Yeshiva University and an MBA in Finance from Columbia Business School 1

1

.

Market Response and Future Outlook

The announcement of Blacher's appointment was well-received by the market, with BullFrog AI Holdings (BFRG) shares rising more than 3% in postmarket trading 2

2

. This positive response suggests investor confidence in the company's leadership transition and future prospects.

As the new CFO, Blacher is expected to build upon the foundation laid by his predecessor, with a focus on enhancing the company's balance sheet strength, improving financial operations, and supporting strategic initiatives. These efforts will be crucial in advancing BullFrog AI's mission to leverage AI and machine learning in drug discovery and development 1

1

.

The company's forward-looking statements indicate a commitment to adapting to new technologies, meeting changing market needs, and maintaining a competitive edge in the AI-driven drug development landscape. However, BullFrog AI also acknowledges the potential risks and uncertainties inherent in the rapidly evolving field of AI and biotechnology 1

1

.